NSCLC

Pathos AI acquires majority stake in DeuterOncology to advance DO-2, a MET inhibitor showing 100% tumor shrinkage in Phase 1 with superior safety profile.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Galera and Obsidian merge in all-stock deal with $350M financing, creating Obsidian Therapeutics ($OBX) focused on TIL cell therapies with funding through 2028.

Nuvectis Pharma will present three posters on NXP900, a first-in-class cancer inhibitor, at April's AACR Meeting in San Diego, highlighting combination and immunotherapy potential.

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.

Junshi Biosciences wins NMPA approval for JS001sc, first domestic subcutaneous anti-PD-1 drug across 12 indications, delivering clinical parity with IV formulation.

MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.

MAIA Biotechnology launches underwritten public offering of common stock and pre-funded warrants to fund clinical trials for its lead cancer therapy ateganosine.

Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.